Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study

Burisch, Johan; Vardi, Hillel; Schwartz, Doron; Friger, Michael; Kiudelis, Gediminas; Kupčinskas, Juozas; Fuméry, Mathurin; Gower‐Rousseau, Corinne; Lakatos, László; Lakatos, Péter L.; D’Incà, R.; Sartini, Alessandro; Valpiani, D.; Giannotta, Martina; Arebi, Naila; Ďuricová, Dana; Bortlík, Martin; Zammit, Stefania Chetcuti; Ellul, Pierre; Pedersen, Natalia; Kjeldsen, Jens; Midjord, J; Nielsen, K R; Andersen, Kjeld; Andersen, Vibeke; Κατσάνος, Κωνσταντίνος; Christodoulou, Dimitrios; Domislović, Viktor; Krznarić, Željko; Sebastian, Shaji; Oksanen, Pia; Collin, Pekka; Barros, Luísa Leite; Magro, Fernando; Salupere, Riina; Kievit, Hendrika Adriana Linda; Goldiş, Adrian; Kaimakliotis, Ioannis; Dahlerup, Jens Frederik; Eriksson, Carl; Halfvarson, Jonas; Fernández, Alberto; Hernández, Vicent; Turcan, Svetlana; Belousova, Elena; Langholz, Ebbe; Munkholm, Pia; Odes, Selwyn; Turk, Nikša; Čuković‐Čavka, Silvija; Nicolaou, Anastasia; Lukáš, Milan; Shonová, Olga; Blichfeldt, Birgitte; Marker, Dorte; Carlsen, Katrine; Weimers, Petra; Aalykke, Clays; Kudsk, Karen; Vind, Ida; Thorsgaard, Niels; Skamnelos, Alexandros; Politis, Dimitrios; Végh, Zsuzsanna; Demenyi, Peterne; Kramli, Szabina Nemethne; Piaz, Giualia Dal; Santini, A.; Girardin, Giulia; Kupčinskas, Limas; Jonaitis, Laimas Virginijus; Valantienė, Irena; Zykus, Romanas; Kučinskienė, Rūta; Lazăr, Daniela; Nikulina, Inna; Castro, Luísa; Pineda, Juan-Ramon; Pereira, Santos; Martínez-Cadilla, Jesús; Sanromán, Luciano; Figueira, M; Ares, D. Martínez; Rodriguez-Prada, J I; Carmona, Amalia; González-Portela, Carlos; Widen, Ulla-Britt; Myers, Sally; Ashton, Katherine M.; Whitehead, Emma

doi:10.1016/s2468-1253(20)30012-1

Cited by 98 publications

(81 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, recent data from the Epi-IBD cohort also highlights the economic impact of smoking on IBD, especially in CD, where smoking cessation has medical and economic benefits[ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations

Berre¹,

Loy²,

Lönnfors³

et al. 2020

WJG

View full text Add to dashboard Cite

BACKGROUND Smoking has detrimental effects on Crohn’s disease (CD) activity while data on ulcerative colitis (UC) are conflicting. Little is known about the use and impact of alternative smoking products in inflammatory bowel diseases (IBD). AIM To understand the patients’ perceptions of the impact of smoking on their IBD and to assess differences between CD and UC patients. METHODS The questionnaire was developed by Philip Morris Products SA in cooperation with European Federation of Crohn's and Ulcerative Colitis Associations. The final survey questionnaire consisted of 41 questions divided in 8 categories: (1) Subject screener; (2) Smoking history; (3) Background information; (4) IBD disease background; (5) Current disease status; (6) Current therapeutics and medications; and (7) Current nicotine/cigarettes use and awareness of the impacts of smoking on IBD. The questionnaire was submitted online from 4 th November 2019 to 11th March 2020 through the European Federation of Crohn's and Ulcerative Colitis Associations website to IBD patients who were current smokers or had a history of smoking. RESULTS In total 1050 IBD patients speaking nine languages participated to the survey. Among them, 807 (76.9%) patients declared to have ever smoked or consumed an alternative smoking product, with a higher proportion of current cigarette smokers among CD patients (CD: 63.1% vs UC: 54.1%, P = 0.012). About two-thirds of the participants declared to have ever stopped cigarette smoking and restarted (67.0%), with a significantly higher proportion among UC patients compared to CD patients (73.1% vs 62.0%, P = 0.001). We also found significant differences between CD and UC patients in the awareness of the health consequences of smoking in their disease and in the perceived impact of smoking on disease activity, for both cigarettes and alternative smoking products. CONCLUSION This survey found significant differences between CD and UC patients in both awareness and perception of the impact of smoking on their disease. Further efforts should be done to encourage smoking cessation for all IBD patients, including UC patients.

show abstract

“…Furthermore, recent data from the Epi-IBD cohort also highlights the economic impact of smoking on IBD, especially in CD, where smoking cessation has medical and economic benefits[ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations

Berre¹,

Loy²,

Lönnfors³

et al. 2020

WJG

View full text Add to dashboard Cite

show abstract

“…In a study of a Danish inception cohort of IBD-patients 2003-2004 and followed until 2015, the cost-benefit effects of biologics on the direct costs were assessed indicating a 'moderately-strong' correlation between the increased costs of biologics and the falling costs of direct expenses, excluding biologics 244 . In the Epi-IBD cohort, a community-based, prospective inception cohort of unselected patients with IBD diagnosed in 2010 at centres in 20 European countries plus Israel and followed for five years, there was during follow-up a continuing increase in expenditure for biologicals for patients with CD accounting for 73% of the cost year 5 with a mean yearly budget for biologicals in CD being 6-fold the cost in UC 245 .…”

Section: Direct and Indirect Costs Of Ibd/ CDmentioning

confidence: 99%

Surgery and stomas in Crohn's disease

Kalman

2021

Linköping University Medical Dissertations

View full text Add to dashboard Cite

This study investigates the evolution of abdominal surgery in treatment of Crohn´s disease (CD) in the era of immunomodulatory drugs and biologicals. It concerns risk of abdominal surgery overall and sub-categories of abdominal surgery, risk of repeat surgery and factors that affect this risk, and risk of getting a stoma. Surgical recurrence is a major clinical problem as repeat procedures are more complex and expose the patients to a higher medical risk both in conjunction with surgery and afterwards. Updated information on abdominal surgery for CD will be of use when making decisions about medical vs surgical interventions.

show abstract

“…4 As a result, biological agents now account for the highest proportion of national healthcare expenditure among patients with inflammatory bowel disease (IBD). 5,6 Infliximab is a chimeric IgG1 antibody that targets the proinflammatory cytokine tumour necrosis factor-alpha (TNFα). 7 Since the end of its patent in 2015, biosimilar products have emerged offering the same efficacy and safety profile as the originator antibody, with a massive reduction in treatment cost.…”

Section: Introductionmentioning

confidence: 99%

“…From the French population perspective, the 5‐year cumulative probabilities of anti‐TNF monotherapy have dramatically increased up to 33.8% and 12.9% after obtaining a diagnosis of Crohn's disease and ulcerative colitis respectively 4 . As a result, biological agents now account for the highest proportion of national healthcare expenditure among patients with inflammatory bowel disease (IBD) 5,6 …”

Section: Introductionmentioning

confidence: 99%

Outcomes after double switching from originator Infliximab to biosimilar CT‐P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12‐month prospective cohort study

Trystram¹,

Abitbol

Tannoury³

et al. 2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundThere are few data regarding multiple switching from the originator Infliximab to its biosimilars.AimTo assess outcomes and patient perspectives in a prospective manner after double switching from Infliximab to the biosimilars CT‐P13 and SB2.MethodsA total of 158 consecutive patients with inflammatory bowel disease (IBD) receiving CT‐P13 maintenance therapy were switched to SB2 and followed for 54 weeks. Patients were stratified according to previous switch from the originator Infliximab to CT‐P13 (double switch group) or not (single switch group).ResultsThe drug persistence was high (94.9%) after 54 weeks. In total, 17 (10.8%) patients experienced loss of response to SB2, including 10 patients who were managed through dose optimisation and continued treatment. No changes were observed in clinical activity scores, fatigue, biological activity and pharmacokinetical parameters after the switch. The safety profile was in line with the current knowledge of Infliximab. According to the Beliefs about Medicines Questionnaire, the patients’ perspectives did not change after switching from CT‐P13 to SB2. The primary patient concerns remained after the switch, which were focused on effectiveness and safety rather than on the molecular differences between originator and biosimilars or socioeconomic benefits. There were also no differences in the concerns and beliefs between the double and single switch groups.ConclusionDouble switching from the originator Infliximab to CT‐P13 and then to SB2 was not associated with an impairment in patient beliefs, while the effectiveness, immunogeniity and safety of anti‐TNF therapy remained stable after 54 weeks of follow‐up.

show abstract

Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study

Cited by 98 publications

References 35 publications

Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations

Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations

Surgery and stomas in Crohn's disease

Outcomes after double switching from originator Infliximab to biosimilar CT‐P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12‐month prospective cohort study

Contact Info

Product

Resources

About